All interviews and presentations from the ANZUP ASM are available to ANZUP Members only. Membership is free for professional disciplines and groups involved in researching and treating cancers of the genitourinary system.
ANZUP Journal Articles 2016
Smith AB, Butow P, Olver I, Luckett T, Grimison P, Toner GC, Stockler MR, Hovey E, Stubbs J, Turner S, Hruby G, Gurney H, Alam M, Cox K, King MT. The prevalence, severity and correlation of psychological distress and impaired healthrelated quality of life following treatment for testicular cancer: a survivorship study. Journal of Cancer Survivorship: Research and Practice 2016; 10(2): 223-233.
Ussher JM, Perz J, Kellett A, Chambers S, Latini D, Davis ID, Rose D, Dowsett GW, Williams S. Health-related quality of life, psychological distress and sexual changes following prostate cancer: a comparison of gay and bisexual men with heterosexual men. Journal of Sexual Medicine 2016; 13(3): 425-434.
Rose, D., Ussher, J., & Perz, J. (2016). Let’s talk about gay sex: Gay and bisexual men’s sexual communication with healthcare professionals after prostate cancer. European Journal of Cancer Care (Engl), [published online ahead of print]. doi: 10.1111/ ecc.12469.
Ussher J. M., Perz, J., Rose, D., Dowsett, G. W., Chambers, S., Williams, S., Davis I, Latini, D. (2016). Threat of sexual disqualification: The consequences of erectile dysfunction and other sexual changes for gay and bisexual men with prostate cancer. Archives of Sexual Behaviour DOI 10.1007/s10508-016- 0728-0 [available open access].
ANZUP Conference Presentations 2016
Toner GC, Whitford HS, Kalinowski P, Grimison PS, Stockler MR, Martin AJ, Davis ID, Olver IN, ANZUP Cancer Trials Group. The impact of chemotherapy on cognition: a longitudinal study in testicular cancer. Genitourinary Cancers Symposium; 7–9 Jan 2016; San Francisco.
ANZUP Journal Articles 2015
Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith
DP. An examination of prostate cancer trends in Australia,
England, Canada and USA: is the Australian death rate too
high? World Journal of Urology 2015; 33(11): 1677–1687.
Hayne D, Stockler M, McCombie SP, Chalasani V, Long A,
Martin A, Sengupta S, Davis ID. BCG+MMC trial: adding
mitomycin C to BCG as adjuvant intravesical therapy for highrisk,
non-muscle-invasive bladder cancer: a randomised phase
III trial (ANZUP 1301). BMC Cancer 2015; 15(1): 432.
Sengupta S, Grimison P, Hayne D, Williams S, Chambers S,
de Souza P, Stockler M, McJannett M, Toner G, Davis ID.
ANZUP—a new co-operative cancer trials group in genitourinary
oncology. BJU International 2015; 115(6): 856-858.
Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi
K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza
H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis
ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME,
Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis
CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker
C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small
EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF & Tombal
B: Management of patients with advanced prostate cancer:
recommendations of the St Gallen Advanced Prostate Cancer
Consensus Conference (APCCC) 2015, Annals of Oncology
Advance Access, 28 June, 2015.
ANZUP Conference Presentations 2015
Blinman P, Davis I, Martin A, Troon S, Sengupta S, Hovey E,
Coskinas X, Kaplan R, Ritchie A, Meade A, Eisen T, Stockler
M. Patients’ preferences for adjuvant sorafenib after resection
of intermediate or high risk renal cell carcinoma in the sorce
trial: What makes it worthwhile? Medical Oncology Group of
Australia Annual Scientific Meeting; 5–7 Aug 2015; Hobart.
Davis ID, Stockler MR, Martin AJ, Marchesin V, Deignan O,
McDermott R, Parulekar WR, North SA, Graham B, Long AP,
Roncolato FT, Yip S, Hague W, Dazo C, Coskinas X, Sweeney C.
Randomised phase 3 trial of enzalutamide in first line androgen
deprivation therapy for metastatic prostate cancer: the ANZUP
ENZAMET trial (ANZUP 1304). American Society of Clinical
Oncology Annual Meeting; 29 May−2 Jun 2015; Chicago.
Lawrence N, Toner G, Martin A, Stockler M, Yeung A, Wong N,
Thomson DB, Gebski V, Yip S, King M, Friedlander M, Quinn D,
Tan TH, Chan H, Mazhar D, Hanning F, Weickhardt A, Jeffery M,
Stevanovic A, Hovey E, Wyld D, Davis ID, Grimison P, and on
behalf of ANZUP. P3 BEP (ANZUP 1302): a randomised phase
3 trial of accelerated versus standard BEP chemotherapy for
patients with intermediate and poor-risk metastatic germ cell
tumours. Clinical Oncological Society of Australia 42nd Annual
Scientific Meeting; 17–19 Nov 2015; Hobart.
Williams SG, Davis ID, Sweeney C, Stockler MR, Martin AJ,
Marchesin V, Deignan O, McDermott R, Long AP, Roncolato
FT, Yip S, Hague W, Tu E, Coskinas X, Nguyen PL. Randomised
phase 3 trial of enzalutamide in androgen deprivation therapy
with radiation therapy for high risk, clinically localised prostate
cancer: the ANZUP ENZARAD trial (ANZUP 1303). American
Society of Clinical Oncology Annual Meeting; 29 May−2 Jun
2015; Chicago.
Ussher, JM: Sexual wellbeing and quality of life after prostate
cancer: A comparison of gay/ bisexual men and heterosexual
men, ANZUP Annual Scientific Meeting, 12-14 July 2015; Sydney.
Ussher, JM; Gay and bisexual men’s experiences of sexuality,
identity and relationships after prostate cancer: A qualitative
analysis, ANZUP Annual Scientific Meeting, 12-14 July 2015;
Sydney.
Yip S, Hague W, Price T, Mitchell P, Davis ID; Brand A;
Rosenthal M; Simes RJ, Stockler MR: Pursuing Biospecimens
Translational Research in Investigator-Initiated Clinical Trials in
Oncology, ACTA International Clinical Trials Symposium, 7-10
October 2015; Sydney
Nguyen P, Williams S, Davis I, Stockler M, Niazi T: Randomised
phase 3 trial of enzalutamide in androgen deprivation therapy
with radiation therapy for high risk, clinically localised, prostate
cancer, ANZUP Annual Scientific Meeting, July 2015; Sydney.
Grummet J, Davis I, Martin A, Buchan N, Chalasani V,
Frydenberg M, Hayne D, Lalak A, Patel M, Williams A, Woo H,
Lawrence N, Chan H, Bishop C, Wong N, Coskinas X, Stockler
M: Randomised phase 3 double-blind placebo-controlled
trial of methoxyflurane with periprostatic local anaesthesia
to reduce the discomfort of transrectal ultrasound-guided
prostate biopsy (Pain-Free TRUS B): ANZUP 1501, Clinical
Oncology Society of Australia Annual Scientific Meeting; 17-19
Nov 2015; Hobart.
Davis ID, Stockler MR, Martin A, Marchesin V, Deignan O,
McDermott R, Parulekar WR, North SA, Graham B, Chowdhury
S, Long AP, Roncolato FT, Yip S, Hague W, Dazo C, Coskinas
X, Sweeny C: Randomised phase 3 trial of enzalutamide in
first line androgen deprivation therapy for metastatic prostate
cancer: the ANZUP ENZAMET Trial (ANZUP 1304). American
Society of Clinical Oncology Annual Meeting; 29 May−2 Jun
2015; Chicago.
Williams SG, Davis IDD, Sweeney C, Stockler MR, Martin
A, Hague W, Coskinas X, Yip S, Tu E, Chan H, Lawrence N,
McDermott R, Hughes S, Marchesin V, Deignan O, Nguyen
PL: Randomised phase 3 trial of enzalutamide in androgen
deprivation therapy (ADT) with radiation therapy for clinically
localised high risk or node-positive, clinically localized, prostate
cancer: ENZARAD (ANZUP 1303). American Society of Clinical
Oncology Annual Meeting; 29 May−2 Jun 2015; Chicago.